BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Huntexil pridopidine: Additional Phase II/III data

A meta-analysis of the Phase II HART and Phase III MermaiHD trials showed that 45 mg twice-daily Huntexil non-significantly improved voluntary motor function by 0.6 points as measured by the mMS subscale of the UHDRS vs. placebo at week 12 (p=0.12), but did significantly improve the endpoint by 1.2 points at week 26 (p<0.01). Additionally, Huntexil significantly improved the TMS of the UHDRS by...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >